Partner with Breethwell: Transform Breathing Health
Breethwell is redefining respiratory wellness by addressing Day Apnea, the subconscious breath-holding or shallow breathing impacting millions. Our patented CMAP (Continuously Monitoring Airway Pressure) device, a wearable IoT solution launching in early 2026, monitors and corrects irregular breathing in real-time. We seek partnerships with breathwork apps, general wellness brands, and leading sleep apnea companies to amplify CMAP’s impact across wellness, therapy, and research. Join us to empower better breathing and healthier lives.
​
Why Partner with Breethwell?
​
Built on over 20 years of research through the Pacific Neuroscience Institute, Breethwell identified a critical gap: daytime breathing irregularities, like Day Apnea and Screen Apnea®, drive hypertension, anxiety, and fatigue, affecting 25 million Americans with tinnitus, 13 million with PTSD, and 19.1 million with anxiety. CMAP’s nasal/oral cannula design outperforms bulky chest-band monitors (e.g., CapnoTrainer, $2,950). Early tests showed nearly all users exhibit breath-holding, with promising reductions in blood pressure and anxiety, positioning CMAP as an ideal partner for breathwork, wellness, and sleep apnea innovators.
​
CMAP: A Versatile Platform
CMAP, a compact (2” x 2.5” x 0.75”) device, tracks airflow, heart rate, and blood oxygen (SpOâ‚‚), connecting via Bluetooth to a smartphone app for real-time alerts and guided exercises. Unlike CPAP machines for sleep apnea, CMAP targets daytime breathing, offering applications for:
Breathwork Apps: Integrates with platforms like Headspace or Breathwrk, enhancing meditation, pranayama, and personalized exercises, tapping a booming wellness trend (Global Wellness Summit, 2021).
General Wellness: Supports mindfulness and stress relief, appealing to brands targeting holistic health.Sleep Apnea: Complements CPAP ecosystems (e.g., ResMed, Philips) as a daytime monitoring tool or home sleep apnea test (HSAT) outside the U.S., with FDA-targeted therapy applications.
Therapy & Research: Aids hypertension, anxiety, and PTSD treatments, with data for clinical studies.Fitness & Pain Management: Optimizes athletic performance and supports therapeutic breathing.With U.S. and international patents pending, CMAP’s affordability ($299 - $499) and wearable compatibility ensure broad adoption.Partnership OpportunitiesBreethwell offers tailored collaborations:Breathwork Apps: License CMAP’s real-time data to create adaptive exercises, boosting user retention and engagement.Wellness Brands: Co-brand CMAP for mindfulness campaigns, reaching wellness-focused consumers.
Sleep Apnea Leaders: Partner with giants like ResMed to integrate CMAP into daytime monitoring or HSAT solutions, expanding market reach.
Healthcare & Research: Deploy CMAP in clinical trials or patient care for hypertension and PTSD, leveraging a 2007 Microsoft study (40% hold breath while emailing).
Corporations: Offer CMAP in wellness programs to combat Screen Apnea (62% of Americans spend 4+ hours on screens, Common Sense Media, 2024).
Partnerships can include API integrations, co-marketing, or joint ventures, maximizing mutual value.
Market Potential
The $9 billion sleep apnea market overlooks daytime breathing, creating a niche for CMAP. Breathwork and wellness are surging, while Screen Apnea affects millions. Partnerships can tap a projected $7.3 billion CPAP market by 2034, with revenue from device sales, in-app purchases (breathwork exercises), consumables (cannulas, SpOâ‚‚ sensors), and licensing. CMAP’s multi-vertical appeal ensures scalability.
Colaborate with US
Partner with Breethwell to shape the future of breathing. Contact us at partner@breethwell.com to explore synergies and join a mission to make every breath count.